Version 2.80

Description

Antibodies to ustekinumab (ATU) have been detected in 6.5% of patients who were receiving ustekinumab for13 months. The presence of ATU is associated with reduced levels of ustekinumab and treatment failure. The number of patients who develop ATU is similar to the number of patients who failed therapy with adalimumab regardless of whether those patients were positive or negative for antibodies to adalimumab. PMID: 26566272 Source: Regenstrief LOINC

Basic Part Properties

Part Name
Ustekinumab Ab
Part Display Name
Ustekinumab Ab
Part Type
Component (Describes the core component or analyte measured)
Created On
2017-05-09
Construct for LOINC Short Name
Ustekinumab Ab

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP250854-9